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FPIN's Clinical Inquiries 
Treatment of Early Parkinson's Disease 
Clinical Question 
What is the best medical therapy for early Parkinson's disease? 
Evidence-Based Answer 
Treatment of early Parkinson's disease with either selegiline (Eldepryl), a dopamine agonist 
(pramipexole [Mirapex], ropinirole [Requip], or bromocriptine [Parlodel]), or the combination of 
levodopa and carbidopa (Sinemet) or levodopa and cabidopa with entacapone (Stalevo) improves 
symptoms and quality of life, but all medication regimens are associated with significant side 
effects (Table 1). There is no compelling evidence favoring a medication option, so treatment 
should be individualized. [Strength of recommendation: A, based on systematic reviews of 
randomized controlled trials (RCTs)] 
TABLE 1 
Medications Commonly Used for Parkinson's Disease 
Generic name 
Brand 
name Initial dosage 
Target 
dosage 
range* 
Common adverse 
effects 
Cost for 
brand 
name 
drug 
(cost for 
generic) 
Levodopa plus 
carbidopa 
Sinemet 10 mg carbidopa 
with 100 mg 
levodopa; 25 mg 
carbidopa with 
100 mg levodopa; 
25 mg carbidopa 
with 250 mg 
levodopa 
(medication three 
times per day)† 
Increase by 
one tablet 
every day or 
every other 
day to a 
maximum of 
eight tablets 
per day 
Dyskinesia, 
dystonia, 
hallucinations, 
hyperkinesia, 
dizziness, fatigue, 
abdominal pain, 
constipation, 
diarrhea, nausea, 
vomiting, urine 
discoloration, 
cardiac 
abnormalities, 
orthostatic 
hypotension 
$84 ($72 
to $85) 
per 
month 
 Sinemet 
CR 
50 mg carbidopa 
with 200 mg 
levodopa two 
times per day 
Increase by 
one tablet 
every three 
days to a 
maximum of 
eight tablets 
per day 
Same as above $121 per 
month 
Levodopa plus 
carbidopa and 
entacapone 
Stalevo 12.5 mg 
carbidopa with 50 
mg levodopa and 
200 mg 
entacapone two 
times per day 
Increase 
slowly to a 
maximum of 
eight tablets 
per day 
Same as above $198 per 
month 
Dopamine 
agonists 
     
Bromocriptine Parlodel 1.25 mg two 
times per day 
Adjust every 
two weeks 
up to 5 
to 20 mg two 
times per day 
Nausea, headache, 
dizziness 
$106 
($66 to 
$70) per 
month 
Pramipexole Mirapex 0.125 mg three 
times per day 
Adjust every 
week up to 
1.5 mg three 
times per day 
Dizziness, 
somnolence, 
hallucinations, 
nausea, edema 
$107 per 
month 
Ropinirole Requip 0.25 mg three 
times per day 
Adjust every 
week up to 1 
mg three 
times per day 
Dizziness, 
somnolence, 
nausea, 
hallucinations, 
edema 
$135 per 
month 
MAOI-B 
Selegiline  Eldepryl  5 mg at breakfast 
and lunch  
No dosage 
titration 
required  
Nausea, dizziness, 
abdominal pain, 
confusion, 
hallucinations 
$81 per 
month  
 
MAOI-B = monoamine oxidase inhibitor type B. 
*-After initiation of therapy, dose should be adjusted to achieve the desired 
therapeutic response rather than to achieve the maximum dosage. 
†-Studies show that patients receiving less than 70 to 100 mg per day of carbidopa 
may experience nausea and vomiting. Usual tablet strength used is 25 mg of 
carbidopa with 100 mg of levodopa. Based on severity of symptoms, some 
physicians choose an initial dosage of four times per day. 
Information from references 19 and 21. 
Evidence Summary 
Parkinson's disease affects more than 1 percent of persons 65 years of age or older. Parkinson's 
disease is associated with resting tremor, cogwheel rigidity, and bradykinesia.1 Early Parkinson's 
disease is defined as a disease duration of fewer than five years or a patient with Parkinson's 
disease who has not developed motor complications from levodopa.1,2 The Unified Parkinson 
Disease Rating Scale (UPDRS) measures the longitudinal course of Parkinson's disease on a 
scale of zero (no disability) to 199 (total disability).1 Treatment should be initiated when 
symptoms begin to cause impairment, disability, or affect quality of life.1,2  
A systematic review1 was performed for the Agency for Healthcare Research and Quality based 
on 49 RCTs of pharmacologic treatment involving 9,968 patients with Parkinson's disease. 
Limitations of the evidence include heterogeneity in the definition of early disease and motor 
fluctuations, variation in the measurement of UPDRS scores (during the "off" and "on" periods), 
and use of levodopa as needed in the dopamine agonist arms of the RCT.1 The focus of this 
systematic review was comparing levodopa plus a dopamine agonist (such as bromocriptine) 
with levodopa alone, for which there was no statistically significant difference (effect size: 0.16; 
95% confidence interval: -0.05 to 0.35).3 The authors of the systematic review concluded that 
the use of levodopa monotherapy is limited by the development of motor fluctuations and drug-
induced dyskinesias. Another significant finding of the systematic review was that treatment that 
mandated levodopa as an adjunct to a dopamine agonist controlled symptoms better than 
treatment that allowed levodopa on an as-needed basis. An earlier Cochrane review3 also stated 
that there was no convincing evidence to support or refute the widespread use of levodopa plus a 
dopamine agonist versus levodopa alone for early disease. 
One large RCT4 directly compared bromocriptine with levodopa in a 10-year treatment of early 
Parkinson's disease. At three years, patients receiving bromocriptine had lower disability scores 
than those in the levodopa arm of the trial; however, the difference was not significant at nine 
years, and there was no overall difference in mortality between the groups. 
In two Cochrane systematic reviews,1,5 patients receiving levodopa for three years were more 
likely to develop dyskinesias (number needed to treat to harm [NNH]: 4) and dystonias (NNH: 5) 
than patients receiving bromocriptine, but there were more dropouts in the bromocriptine group 
because of intolerable side effects (NNH: 4).5-7 More recent RCTs8-10 compared the newer 
dopamine agonists pramipexole and ropinirole with levodopa and found that levodopa was 
associated with more dyskinesia and motor fluctuation (NNH: 3 to 4). By 48 months, however, 
the occurrence of disabling dyskinesias was uncommon and did not differ between pramipexole- 
and levodopa-treated patients.10 Pramipexole was more likely to cause somnolence (NNH: 7) 
than levodopa.8,10 Levodopa was more effective in improving the total UPDRS score (9.2 
versus 4.5 points at two years; P < .001) but was no better than ropinirole at improving scores on 
activities of daily living scales.8,9 A meta-analysis reported that pramipexole and ropinirole 
were twice as likely to be associated with hallucinations, somnolence, and edema than 
levodopa.11 Another dopamine agonist, pergolide (Permax), should be avoided because of its 
recent association with restrictive valvular heart disease.12 
RCTs have found that selegiline improves symptoms of Parkinson's disease and delays the need 
for levodopa therapy for up to nine to 12 months.2,5,13 However, one open-label trial found that 
selegiline compared with placebo significantly increased mortality after 5.6 years of monitoring 
(NNH: 10).14 This finding was not replicated in other RCTs and may have been the result of the 
open study design leading to bias in physicians' decisions about treatment withdrawal.14 A 
recent meta-analysis found no increase in mortality in patients with Parkinson's disease taking 
selegiline.15 
Anticholinergic agents (e.g., benztropine [Cogentin] and trihexyphenidyl [Artane]) should be 
avoided because of neuropsychiatric and cognitive adverse effects.16 Based on Cochrane 
reviews,17,18 there also is a lack of evidence to support the use of beta-blockers or amantadine 
(Symmetrel) for Parkinson's disease symptoms. The combination of levodopa and carbidopa, 
with entacapone ([Comtan] a selective and reversible catechol O-methyltransferase inhibitor) is 
suggested for patients currently receiving levodopa who experience end-of-dose depreciation. 
Switching to this combination may allow for a dosage reduction in levodopa but has not been 
shown to improve the UPDRS score. It is not recommended as an initial agent because of its 
higher cost and lack of proven benefit in patients with early Parkinson's disease.19 This answer 
updates previous answers from the Family Physicians Inquiries Network that reviewed aspects of 
this topic.2,13 
Recommendations from Others 
The American Association of Neurology (AAN) recommends levodopa or a dopamine agonist 
for initial therapy of Parkinson's disease, depending on the need to improve motor disability 
(better with levodopa) or lessen motor complications (fewer with a dopamine agonist). The AAN 
also comments that sustained-release levodopa offers no benefit for motor complications when 
compared with the immediate-release products.20 Selegiline was mentioned as an alternative for 
the initial symptomatic treatment of Parkinson's disease, and was thought to have no convincing 
evidence for increased mortality.20 
Clinical Commentary 
The trigger for initiating treatment of Parkinson's disease is interference with activities of daily 
living or symptoms significantly affecting quality of life. These changes are highly subjective, 
relating to the patient's ability to tolerate deviations from their normal state. Physicians 
commonly try a dopamine agonist first because levodopa may have a limited effective duration 
of use. Selegiline also is acceptable as first-line therapy. Each drug should be started at a low 
dosage and be titrated slowly. 
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